Life Science Partnering Conferences: Evaluating the ROI

By Cameron Hurlburt, Director of Business Development, LSN

Greg Mannix VP of European Sales at Life Science Nation is also CEO of Novaurum Biosciences and has attended 15 life science partnering conferences in the last two years as a startup CEO. After this extensive experience, he shares his insights on whether these events are worth the investment and what constitutes a good return on investment (ROI) in terms of outcomes and the number of investor meetings secured. Attending partnering conferences can be a significant investment for life science companies, especially startups and early-stage firms. Mannix emphasizes the importance of carefully evaluating the potential ROI before committing resources.

A successful conference should yield tangible outcomes, such as securing funding, establishing strategic partnerships, or gaining valuable industry insights. Mannix suggests that a good ROI can be measured by the number of quality investor meetings scheduled during the event. “For a conference to be considered successful, I aim to secure at least 10-15 meetings with potential investors or partners that align with our company’s goals and stage of development,” Mannix explains. “These meetings should lead to meaningful discussions and potential collaborations or investment opportunities.”

To maximize the value of partnering events, Mannix recommends a strategic approach. Thorough preparation, targeted networking, and effective follow-up are crucial. “It’s essential to research the attending investors and companies beforehand and strategically request meetings with those that are the best fit,” Mannix advises. “During the event, actively participate in panel discussions, workshops, and networking sessions to gain industry insights and make valuable connections.” Mannix also emphasizes the importance of prompt and professional follow-up after the conference. “Timely and personalized communication with the contacts made during the event can significantly increase the chances of securing partnerships or investments,” he adds.

RESI Europe is taking place in Barcelona on June 17 (in-person) and June 18-19 (virtual). This conference aims to connect startups and early-stage investors, offering a platform for fundraising and partnership opportunities. With a 1:1 ratio of investors to companies and over 250 life science investors in attendance, RESI Europe promises to maximize the number of meetings and potential collaborations. Partnering has opened, and you can register today to secure meeting slots while they are still available.

While life science partnering conferences require an investment, they can provide substantial returns in terms of funding, partnerships, and industry insights when approached strategically. By carefully evaluating the potential ROI, preparing thoroughly, and actively engaging in networking and follow-up, companies can maximize the value of these events and propel their growth in the life science industry.

RESI-Europe-2024-Banner-1100pxw

Hot Investor Profile: Family Office with Accelerator Arm Invests Up to $10M in Early Clinical Stage Therapeutics, With Strong Interest in Biologics 

A family office based in the US has a focus on the social impact as an overall investment mandate. The firm aims to fund cutting-edge therapeutics companies, and is open to both early and later-stage assets. The firm will invest globally. The firm has an accelerator arm, for which the firm is seeking companies with pre-clinical and clinical therapeutics with a minimum initial investment of $1M-$10M, with the possibility of follow-on investments. The firm itself generally invests in companies with lead assets in Phase I – III clinical trials, and the amount of the allocation is based on the raise and pre-money valuation of the company. 
 
The firm is looking for therapeutics companies, with a particular interest in biologics assets such as antibody-based technologies, cell and gene therapies. The firm mandate focused on regenerative and personalized medicine in oncology, neurodegenerative, orphan, and rare disease applications. 
 
The firm will only consider companies that have more than two assets in the pipeline and experienced management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Profile: USA-Based VC Firm Seeks Therapeutics and Digital Health Companies With Validated Proof-of-Concept Across the Globe

A venture capital fund based in the US is currently making investment out of a $150-million-dollar fund. The firm is looking to make 15 additional investments with allocations generally in the $1-$3 million range. The firm is looking to make equity investments and is open to investing in companies globally. 
 
The firm is interested in therapeutic companies developing small molecules for inflammation, infectious and autoimmune disease and stays away from biologics, cell and gene therapy. The firm is also interested in digital health and mobile health services, AI in healthcare, B2B2C medical devices. The firm is looking for companies with some level of proof-of-concept data either in vivo or in vitro up until Phase II of clinical trials. As for digital health, the firm is looking for scalable SAAS models, novel types of healthcare delivery, point-of-care diagnostics and patient’s self-management tools. 
 
The firm is willing to work with incomplete management teams, often working with IP that has just recently spun out of a university. The firm is willing and able to act as a lead or co-investor in financing rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Profile: VC Firm Invests Up to $30M With Opportunistic Mandate Across All Life Science and Healthcare Sectors, Including Platform Technologies 

A venture capital firm looks to participate in pre-seed to pre-IPO funding, and will typically make between 15 and 20 new investments per year and will typically make follow up investments in existing profile companies. Typical investments range between USD $100k-30M. The firm will utilize various capital structures as determined on a case-by-case basis including equity investments, debt, convertible loans, and SAFEs. The firm invests primarily in companies in the Boston area, but open to opportunities outside of the region. 
 
The firm will make investments across all modalities within the medical devices, diagnostics, and digital health sectors. The firm has made and will consider investments in therapeutics as well but prefers to focus on platform technologies. The firm will invest in therapeutics that are pre-NDA as well as medical and diagnostic technology that is in development and clinical. The firm will invest in all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will consider companies across all indications. 
 
The firm will work with both experienced and inexperienced management teams but tends to avoid management teams led by a journeyman CEO. The firm will participate as a lead investor, co-investor, and follow-on investor. The firm will take an active board seat if acting as the lead investor but tends to take a board observer seat if acting as a co-investor. The firm will not take any board seat if acting as a follow-on investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Profile: USA-Based VC Firm Invests in Pre-Seed to Series A Life Science & HealthTech Companies With Inaugural Fund

A venture capital fund headquartered in the US is investing with its first fund, and has invested in 15 portfolio companies to date, with the majority being in the Life Sciences and HealthTech sectors. The firm plans to invest in two-or-three new portfolio companies and make one or two additional follow-on investments. The firm typically makes Pre-Seed, Seed and Series A investments ranging in size from $250K to $1M, and its largest total investment (including follow-ons) in any one company is $3.25M. The firm is preparing to launch its Fund II later in 2024. 
 
The firm invests primarily in the Life Sciences and HealthTech sectors and in a wide range of sub-sectors within those sectors. The firm is sector and subsector agnostic and is open to evaluating different types of technologies. 
 
The firm invests in companies with growth-minded founders with proven track records, defensible market positions, and the ability to be positive cash-flow within 12-24 months. The firm is minority-owned and is committed to managing a diverse portfolio of companies with the potential to deliver above-average returns, including companies with minority, female and SEDI founders. The firm is an active investor that can provide valuable de-risking strategic and operational guidance and support through its venture studio, which helps portfolio companies reduce the risk of costly mistakes, get to market sooner and scale faster. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Partnering for RESI Europe Launches Next Week 

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wpExciting news! The partnering platform for RESI Europe is launching on Monday, May 27. This unique platform allows companies and investors to request meetings based on their fit in technology and stage of development.

Attend In-Person or Virtually

Whether you plan to attend in person in Barcelona on Monday, June 17 or participate virtually on June 18-19, you can take advantage of this powerful partnering tool.

Targeted Meeting Requests

Companies attending RESI can review attending investors’ interests with pre-populated profiles from LSN’s Investor and Licensing Partner Database. This allows you to make targeted meeting requests, maximizing your chances of successful partnerships.

Strategies for Successful Partnering

To help you make the most of this opportunity, LSN recently hosted a webinar on strategies for successful partnering. Check out the recording here to learn how to improve your partnering game.

Upcoming Webinars

We’ll also be holding webinars on how to navigate the RESI partnering platform and use it to your best advantage after the partnering launch. Life Science Nation will host Partnering Tutorials on May 30 and June 13, 10 AM ET

  • May 30, 2024 10:00 AM ET | Partnering Tutorial – Sign Up
  • June 13, 2024 10:00 AM ET | Partnering Tutorial – Sign Up

Register for RESI Europe Now

Haven’t registered yet? Don’t miss out on this incredible opportunity! Register here to join us at RESI Europe.

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw

Announcing RESI Europe’s Seed Fund Panel Lineup

By Faith Patenaude, Investor Research Analyst, LSN

Faith

The benefit of attending RESI Europe is not only due to the partnering and networking, but also the chance to learn from active investors on a variety of panel topics featured throughout the conference. Taking place in person June 17th and virtually June 18th – 19th, RESI Europe will feature a dynamic range of panels covering topics such as Oncology Innovation, Early-Stage Therapeutics, Cross Boarder Investments, and more!

We are excited to present our Seed Funds panel, taking place at 9:00AM June 17th, featuring 6 accomplished and seasoned investors. These experts, all from firms specializing in early-stage investments, will share their knowledge on key topics such as the level of proof-of-concept validation required for seed funding and the significant roles investors play in the early stages of companies. Additionally, they will discuss strategies on how to balance the high risks of early investments with the potential for increased returns. The panel will feature the below investors:

RESI Europe Seed Fund Panel Speakers

Farzad-Abdi-Dezfuli
Farzad Abdi-Dezfuli
Partner
Sarsia
Jorge-Blasco
Jorge Blasco
Venture Partner (Spain)
Lumo Labs
Emma-Gasol
Emma Gasol
Investment Director
AdBio partners
Soyoung-Park
Soyoung Park
Venture Partner (US & Europe)
VU Venture Partners
Sara-Secall
Sara Secall
Partner
Inveready Asset Management
Jaromir-Zahrádka
Jaromir Zahrádka
CEO & Managing Partner, i&i Biotech Fund
i&i Bio

By attending RESI Europe, you will have the opportunity to not only foster meaningful connections but gain valuable knowledge to support your fundraising efforts.

Don’t miss out on this incredible opportunity to learn from top investors and network with industry leaders. Join us in person on June 17th or virtually on June 18th and 19th. We look forward to seeing you at what promises to be another exceptional conference.

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw